<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> where the majority of patients are long-term survivors secondary <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> are a well-documented complication </plain></SENT>
<SENT sid="1" pm="."><plain>The survival of those who develop secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>/<z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is historically said to be extremely poor </plain></SENT>
<SENT sid="2" pm="."><plain>This study from the BNLI database of over 4900 patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> reports long-term follow-up of 30 patients with <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Five patients have survived at least 5 yr (1&gt;12 yr) from the time of diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These patients were significantly younger (p=0.03) than those who succumbed to this complication and each also had standard or favourable risk cytogenetics </plain></SENT>
<SENT sid="5" pm="."><plain>The actuarial 5- and 10-yr survival rates are 17.4% (7.7-34.9%, 95% CI) and 8.7% (1.9-31.7%, 95% CI), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>There is therefore a subgroup of patients who will achieve long-term survival despite the development of secondary <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> </plain></SENT>
</text></document>